NCT00281294View on ClinicalTrials.gov

A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis

PHASE2TerminatedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 31, 2005

Study Completion Date

December 31, 2006

Conditions
Arthritis, Rheumatoid
Interventions
DRUG

Fontolizumab

Trial Locations (9)

12206

The Center for Rheumatology, Albany

16635

Altoona Center for Clinical Research, Duncansville

60612

Rheumatology Associates Clinical Research, Chicago

80230

Denver Arthritis Clinic, Denver

83814

Coeur d Alene Arthritis Clinic, Coeur d'Alene

90048

Wallace Rheumatic Study Center, Los Angeles

94304

Stanford University Medical Center-Div. of Rheumatology, Palo Alto

98101

Benaroya Research Institute at Virginia Mason, Seattle

48910-8595

Justus J. Fiechtner MD PC, Lansing

Sponsors
All Listed Sponsors
lead

PDL BioPharma, Inc.

INDUSTRY

NCT00281294 - A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter